Back to Search
HAROLD BAYS, MD
MD
Endocrinology, Diabetes & Metabolism Physician
NPI: 1316953920IndividualAccepts Medicare
Specialties, Licenses & Credentials
Endocrinology, Diabetes & Metabolism PhysicianPrimary
Internal Medicine — Endocrinology, Diabetes & Metabolism
Code: 207RE0101X
24037(KY)
CMS Specialties
PrimaryENDOCRINOLOGY
Education
UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE
Class of 1984
Clinical Trials (3)
3
Linked Trials
0
Recruiting
3
With Results
Study of Raisins Versus Alternative Snacks in Patients With Type 2 Diabetes Mellitus
NCT01677936COMPLETEDPHASE4PRINCIPAL_INVESTIGATOR
A Single Research Site Bile Acid Sequestrant Acceptability (BASA) Scale Pilot Validation Study
NCT01062269COMPLETEDPHASE4PRINCIPAL_INVESTIGATOR
Comparison of Colesevelam Hydrogen Chloride (HCl) Powder For Oral Suspension Versus Generic Cholestyramine Through Use of the Bile Acid Sequestrant Acceptability (BASA) Scale
NCT01122108COMPLETEDPHASE4PRINCIPAL_INVESTIGATOR
Research & Publications (20)
Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients.
PMID 19243712·Clin Ther·2009
8-other
Review of ARBITER 2: extended-release niacin added to statin therapy slows the progression of atherosclerosis. Commentary.
PMID 19332979·Postgrad Med·2009
8-other
From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus.
PMID 19232040·Curr Med Res Opin·2009
6-review
Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia.
PMID 18782465·Curr Med Res Opin·2008
4-observational
Comparison of self-reported survey (SHIELD) versus NHANES data in estimating prevalence of dyslipidemia.
PMID 18346311·Curr Med Res Opin·2008
4-observational
Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects.
PMID 18852398·Arch Intern Med·2008
4-observational
Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians.
PMID 18536782·Drugs Today (Barc)·2008
7-preclinical
Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.
PMID 18327998·Expert Rev Cardiovasc Ther·2008
6-review
Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity.
PMID 18327995·Expert Rev Cardiovasc Ther·2008
6-review
The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys.
PMID 17493087·Int J Clin Pract·2007
4-observational
Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus.
PMID 17588297·Curr Med Res Opin·2007
3-trial
Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk.
PMID 17761111·Curr Treat Options Cardiovasc Med·2007
8-other
A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus.
PMID 17907108·Diab Vasc Dis Res·2007
2-rct
Prevalence of self-reported diagnosis of diabetes mellitus and associated risk factors in a national survey in the US population: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes).
PMID 17915014·BMC Public Health·2007
8-other
Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors.
PMID 18078024·Vasc Health Risk Manag·2007
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3288 ILLINOIS AVE, SUITE 100
LOUISVILLE, KY 40213 - Phone
- (502) 515-6621
Quick Facts
- NPI
- 1316953920
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 42
- Clinical Trials
- 3
- Publications
- 20
Are you this provider?
Claim Your Profile